Benjamin A. Thuma - Concepedia

Author

Benjamin A. Thuma

Also Known As

Benjamin A Thuma, Benjamin A. Thuma, Benjamin Thuma, James R. Southers, Thuma, B., Thuma, B.A., Thuma, Benjamin, Thuma, Benjamin A.

Publications

838

Citations

H-Index

Concepts

All Affiliations

Pfizer (United States)Lawrence Berkeley National Laboratory University of California, Berkeley

About

Benjamin A. Thuma is an author at Pfizer (United States) specializing in medicine, medicinal chemistry, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	653
2	Natural Sciences	10	10	633
3	Biochemistry	9	9	481
4	Biomolecular Engineering	2	2	185
5	Cell Biology	1	1	152

Benjamin A. Thuma

Publications

805

Citations

H-Index

Page 1

	Year	Citations
Receptor-Mediated Delivery of CRISPR-Cas9 Endonuclease for Cell-Type-Specific Gene Editing Romain Rouet, Benjamin A. Thuma, Marc D. Roy, Journal of the American Chemical Society Molecular BiologyAsialoglycoprotein Receptor LigandsGenome EngineeringCrisprAntisense Therapy	2018	152
Discovery of a Clinical Candidate from the Structurally Unique Dioxa-bicyclo[3.2.1]octane Class of Sodium-Dependent Glucose Cotransporter 2 Inhibitors Vincent Mascitti, Tristan S. Maurer, Ralph P. Robinson, Journal of Medicinal Chemistry Pharmaceutical ScienceClinical CandidatePharmacotherapyChemical BiologyPharmaceutical Chemistry	2011	133
Efficient Liver Targeting by Polyvalent Display of a Compact Ligand for the Asialoglycoprotein Receptor Carlos Sanhueza, Michael M. Baksh, Benjamin A. Thuma, Journal of the American Chemical Society Drug TargetMedicinal ChemistryAsialoglycoprotein ReceptorBiochemistryCompact Ligand	2017	108
Discovery of PF-06835919: A Potent Inhibitor of Ketohexokinase (KHK) for the Treatment of Metabolic Disorders Driven by the Overconsumption of Fructose Kentaro Futatsugi, Aaron Smith, Meihua Tu, Journal of Medicinal Chemistry	2020	69
Discovery of Fragment-Derived Small Molecules for in Vivo Inhibition of Ketohexokinase (KHK) Kim Huard, Kay Ahn, Paul A. Amor, Journal of Medicinal Chemistry Metabolic SyndromeMedicinal ChemistryVivo InhibitionDrug TargetBiochemistry	2017	49
C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization Ralph P. Robinson, Vincent Mascitti, Carine M. Boustany‐Kari, Bioorganic & Medicinal Chemistry Letters C-5 SpirocyclizationSugar ModificationsMedicinal ChemistryBiochemistryMedicine	2010	43
Development of an Early-Phase Bulk Enabling Route to Sodium-Dependent Glucose Cotransporter 2 Inhibitor Ertugliflozin David J. Bernhardson, Thomas A. Brandt, Catherine A. Hulford, Organic Process Research & Development PharmacotherapyComplex ApiPharmaceutical ChemistryMolecular PharmacologyMedicinal Chemistry	2014	43
Small Molecule Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Hit to Lead Optimization of Systemic Agents Allyn T. Londregan, Liuqing Wei, Jun Xiao, Journal of Medicinal Chemistry Drug TargetSubtle Structural ChangesLead IdentificationPharmacotherapyChemical Biology	2018	43
PF-07059013: A Noncovalent Modulator of Hemoglobin for Treatment of Sickle Cell Disease Ariamala Gopalsamy, Ann Aulabaugh, Amey Barakat, Journal of Medicinal Chemistry	2020	40
On the importance of synthetic organic chemistry in drug discovery: reflections on the discovery of antidiabetic agent ertugliflozin Vincent Mascitti, Benjamin A. Thuma, Aaron Smith, MedChemComm Medicinal ChemistryPharmaceutical ScienceBioorganic ChemistryBiochemistryNatural Sciences	2012	33

Page 1